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Abstract
Background: Existing dementia risk scores require collection of additional data from patients, limiting their use in
practice. Routinely collected healthcare data have the potential to assess dementia risk without the need to collect
further information. Our objective was to develop and validate a 5-year dementia risk score derived from primary
healthcare data.
Methods: We used data from general practices in The Health Improvement Network (THIN) database from across
the UK, randomly selecting 377 practices for a development cohort and identifying 930,395 patients aged 60–95 years
without a recording of dementia, cognitive impairment or memory symptoms at baseline. We developed risk algorithm
models for two age groups (60–79 and 80–95 years). An external validation was conducted by validating the model on
a separate cohort of 264,224 patients from 95 randomly chosen THIN practices that did not contribute to the
development cohort. Our main outcome was 5-year risk of first recorded dementia diagnosis. Potential predictors
included sociodemographic, cardiovascular, lifestyle and mental health variables.
Results: Dementia incidence was 1.88 (95 % CI, 1.83–1.93) and 16.53 (95 % CI, 16.15–16.92) per 1000 PYAR for those
aged 60–79 (n = 6017) and 80–95 years (n = 7104), respectively. Predictors for those aged 60–79 included age, sex,
social deprivation, smoking, BMI, heavy alcohol use, anti-hypertensive drugs, diabetes, stroke/TIA, atrial fibrillation,
aspirin, depression. The discrimination and calibration of the risk algorithm were good for the 60–79 years model; D
statistic 2.03 (95 % CI, 1.95–2.11), C index 0.84 (95 % CI, 0.81–0.87), and calibration slope 0.98 (95 % CI, 0.93–1.02). The
algorithm had a high negative predictive value, but lower positive predictive value at most risk thresholds.
Discrimination and calibration were poor for the 80–95 years model.
Conclusions: Routinely collected data predicts 5-year risk of recorded diagnosis of dementia for those aged 60–79, but
not those aged 80+. This algorithm can identify higher risk populations for dementia in primary care. The risk
score has a high negative predictive value and may be most helpful in ‘ruling out’ those at very low risk from further
testing or intensive preventative activities.
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Background
More than 115 million people are predicted to have de-
mentia by 2050 [1], with huge associated health and social
care costs [2]. There is both epidemiological [3, 4] and
policy [5] support for the identification and management
of modifiable risk factors for dementia to delay dementia
onset. Around a third of Alzheimer’s disease cases might
be attributable to potentially modifiable risk factors
(diabetes, mid-life hypertension, mid-life obesity, de-
pression, physical inactivity, smoking, low education)
[3]. It has been estimated that a reduction in the seven
main modifiable risk factors by 10–25 % would pre-
vent an estimated 1–3 million dementia cases world-
wide [4]. There is a strong drive internationally for
clinicians to be more pro-active in dementia diagnosis
[6, 7]. There is, however, a limited evidence base for
current approaches to dementia screening and case-
finding [8, 9] and further work needs to be completed
to validate new methods across different settings, in-
cluding primary care [9].
Many multi-factorial prognostic dementia risk models
have been developed based on neuropsychological testing
and sociodemographic, health, lifestyle, and environmental
variables from a range of cohort studies, e.g. [10–20]. These
have had variable discriminating power [10, 11], there is no
one model that is recommended for population based set-
tings [11], and none are widely used in practice. These risk
scores entail collecting extra information from patients that
would not form part of routine clinical care for the general
population, for example, on fish oil intake [20], pesticide ex-
posure [20], needing assistance with money or medication
[19], years of education [12, 19, 20], depression symptom
score [19, 20], genotype [12–14], or neuropsychological
testing [13, 15, 17, 18], making these scores potentially
more difficult and costly to implement to large populations
in non-specialized clinical settings. One tool has recently
been developed as a brief screening indicator to identify a
high risk population for cognitive screening in primary care,
using data from four cohort studies [19]. However, three of
the seven factors in this tool are not routinely recorded in
General Practitioner (GP) records in the United Kingdom
(UK), and would have to be collected from patients indi-
vidually. Validated risk scores developed using routinely
collected primary care data have been used in practice for
other disease areas, such as cardiovascular disease predic-
tion, where they performed better than standard algorithms
(e.g. Framingham) originally derived from cohort studies
[21]. These scores can be easy to implement and calculated
without collecting extra new information from the patient.
They can be used to risk stratify an eligible practice popula-
tion, as the process is automated and uses data already in
medical records. No dementia risk model has yet been de-
veloped and validated using routinely collected primary
care data in the general population. Our study objectives
were to develop and validate a 5-year dementia risk score
utilizing routinely collected data from a large nationally
representative primary care database in the UK.
Methods
Study design
Cohort studies using routinely collected data; develop-
ment and validation of a 5-year risk score for predicting
newly recorded dementia diagnoses.
Setting and data source
We used The Health Improvement Network (THIN)
primary care database, which derives data from routine
clinical practice in the UK [22]. Around 6 % of General
Practices in the UK contribute data to the THIN data-
base, which contains nearly 12 million patients and is
broadly representative of the UK population [22, 23].
Data is collected longitudinally during routine care and
includes consultations, symptoms, diagnoses, investiga-
tions, health measurements, prescriptions, surgical proce-
dures, and referrals. Diagnoses from secondary care and
other health information received by the practice are coded
and entered using Read codes, a hierarchical coding system
which maps onto ICD-10 codes, but which also includes
symptom descriptions. THIN data is collected and anon-
ymized centrally and linked by postal (zip) code for 150
households to population census data, including neigh-
bourhood deprivation (quintiles of Townsend deprivation
index) [24]. Diagnostic and prescribing information are
generally well recorded and accurate [25, 26] and have
been successfully used in numerous studies [22], including
dementia [27–29]. Further, THIN data are subject to a
range of quality assurance procedures [30, 31]. A validation
study of dementia recording suggested a specificity of a GP
recorded dementia diagnosis of 83 % and no false negatives
in a small sample without recorded dementia [27].
We randomly selected 377 practices from 472 eligible
practices providing acceptable quality data to THIN during
our study period for a development cohort. The remaining
95 randomly selected eligible practices formed a com-
pletely separate validation cohort.
Participants
In both development and validation cohort studies we
included individuals aged between 60 and 95 years con-
tributing to the THIN database between January 1, 2000,
and December 31, 2011. We excluded individuals with re-
corded dementia, cognitive impairment, memory symp-
toms and confusion prior to study entry, those with an
exclusion diagnosis indicating specific sub-types of demen-
tia syndrome (Parkinson’s disease, Huntingdon’s disease,
Pick’s disease, alcohol-induced dementia, dementia in other
conditions, Human Immunodeficiency Virus (HIV), Lewy
body disease, Cruetzfeldt-Jacob Disease), and those with
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less than a year’s follow-up data, to allow time for patient
history and risk factor information to be recorded (Fig. 1
and Additional file 1: Figure A1).
Follow-up period
Follow-up time was restricted to a maximum of 5 years
in both cohort studies. The start of follow-up was the
latest of: 1) January 1, 2000; 2) when the individual
turned 60 years; 3) one year following new registration
with a THIN practice; 4) one year after the practice met
standard criteria for accurate recording of deaths, consult-
ation, health measurements, and prescribing [30, 31]. The
end date was the earliest of dementia incident date, 5 years
follow-up, patient died, patient developed an exclusion
diagnosis (as listed above), patient left practice, practice
left THIN database, or December 31, 2011.
Main outcome
Newly recorded dementia diagnoses, including Alzheimer’s
disease, vascular dementia, and unspecified or mixed de-
mentia, but excluding dementia diagnoses associated with
Parkinson’s disease, Lewy body dementia, Huntingdon,
Picks, HIV, and drug-induced and alcohol-related dementia
(Read code lists available from the authors) were the pri-
mary outcome.
Risk factor measurements
Based on potential risk factors for dementia [3, 4, 32]
available in THIN, we examined the following as pre-
dictor variables in the risk model:
(1) Sociodemographic measures: age (years), sex, social
deprivation (quintiles of Townsend Index), calendar
year at baseline (to account for temporal trends).
(2) Health status/lifestyle measurements: smoking status
up to 5 years prior to baseline (current, non-smoker
or ex-smoker), body mass index (BMI), lipids
(total cholesterol/ high density lipoprotein (HDL)
cholesterol ratio), systolic blood pressure (SBP),
history of heavy alcohol use (more than 56 units per
week for men/49 units per week for women), or a
Read-code entry in their medical records indicating
an alcohol problem.
(3) Medical diagnoses: diabetes, coronary heart
disease (CHD), stroke/transient ischemic attack
(TIA), or atrial fibrillation at any time prior to
baseline. Current (in 12 months prior to baseline)
depression diagnosis/treatment with antidepressant
medication, anxiety diagnosis/treatment with
anxiolytic medication.
(4) Prescription medication: As listed in (3) and
anti-hypertensive drugs, hypnotic medication,
statins, aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs). Patients were
identified as exposed to medications if they had
received at least two consecutive prescriptions in
the 12 months before baseline.
Analysis
For both the development and validation cohort studies
the study population was divided into two groups: those
aged 60–79 years and aged 80–95 at baseline. At age
Start: 989,524 patients aged 60 to 95 
years in 377 practices
Exclude: 
Patients with a history at baseline of:
Alcohol-induced dementia n=174
Drug-induced dementia n=0
Dementia in other conditions NOS n=139
HIV n=155
Huntingdon’s n=151
Lewy body disease n=136
Parkinson’s n=14,763
Pick’s n=34
CJD n=1
973,971 patients with no exclusion 
diagnoses at baseline in 377 practices
Exclude: 
18,619 patients with a history of dementia at 
baseline
13,485 patients already experiencing 
possible prodromal symptoms (memory loss, 
confusion, cognitive decline)
941,867 patients in 377 practices 
Exclude: 
11,472 patients with no data on social 
deprivation
930,395 patients in 377 practices
Fig. 1 Flowchart of derivation of the development cohort
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80 years, a sharp increased risk of dementia has previ-
ously been found [19], and in our population there were
differences in the distribution of risk factors and their
associations with dementia in those aged 60–79 years
and older individuals. We considered additional stratifi-
cation by sex but age-adjusted risk factor associations
with dementia in men and women were similar, justifying
combining both sexes in a single model. Separate model
development was carried out for the two age groups in
the development cohort and separate validation and
calibration was performed for each age group in the
validation cohort. Analyses were performed using Stata
version 12.1.
Sample size calculation
We conservatively estimated that 20 events were re-
quired per coefficient to fit a risk model based on studies
evaluating the relationship between the number of
events and the performance of a risk prediction model,
which have shown that 15 events at least may be re-
quired to achieve a satisfactory level of model calibration
[33]. There were a total of 25 coefficients for all the pre-
dictors initially considered, corresponding to 500 de-
mentia events needed. Applying an inflation factor to
adjust for clustering within practices of 10.741 for the
60–79 years age model (based on intra-class correlation
coefficient of 0.00117, estimated from the data, and a
mean cluster size of 2,122 people aged 60–79 years per
practice), corresponded to a total of 500 × 10.741 = 5,371
dementia events. For the 80–95 years model, the infla-
tion factor was 10.915 (based on intra-class correlation
coefficient of 0.00863 and a mean cluster size of 346
people aged 80–95 years per practice), which corresponded
to a total of 500 × 10.915 = 5,458 dementia events.
Missing data imputation
We used the two-fold Fully Conditional Specification al-
gorithm method for multiple imputation of longitudinal
clinical datasets to impute missing data for both fixed
(smoking and height) and time-varying variables (total
cholesterol and HDL cholesterol, SBP and weight) in
both the development and validation cohorts [34]. This
algorithm is an efficient way to use the full longitudinal
patient record rather than just the baseline measure-
ments to inform the imputation. Missing data in the
validation cohort was imputed separately from that in
the development cohort. The remaining variables were
complete. The imputation model included all variables
in the analysis model, plus the outcome and cumulative
hazard function. In the backwards elimination process,
the variables were included in the final model if retained
in 7 out of 10 imputed datasets to avoid over-selection
of the variables [35].
Development cohort: model development
For each age group (60–79 years and 80–95 years), we
derived the dementia risk score using a Cox proportional
hazards regression model, with robust standard errors to
account for clustering of individuals within general prac-
tices. The assumption of proportional hazards was
checked using plots of the log cumulative hazard func-
tion and Schoenfeld residuals. Continuous variables were
centred and the assumption of a linear relationship was
assessed using fractional polynomials, visual checks by
plotting graphs of the log hazard ratio by increasing
category of the continuous variable, and by inclusion of
squared and cubic terms in the Cox models; transfor-
mations were made when linear relationships were not
confirmed.
All variables were included in the full model prior to
backwards elimination. We used backwards elimination
to determine which variables should be retained, using
the Akaike Information Criteria. After the elimination
process we considered the interaction terms systolic
blood pressure*anti-hypertensive medication and lipid
ratio*statin prescriptions. Interactions were retained if
significant and clinically meaningful.
Validation cohort: validation and calibration
For each age group, the model developed using the de-
velopment cohort was applied to the validation cohort,
to assess performance. We assessed the discriminative
performance of the dementia risk models by computing
the Uno’s C [36] and Royston’s D [37] statistics for the
validation cohort. Uno’s C and Royston’s D statistics
were chosen as they have been shown to be less biased
in the presence of censored data than other discrimina-
tive statistics [36, 37]. Each validation statistic was esti-
mated separately for each imputed validation dataset,
and then combined using Rubin’s rules to obtain an
overall validation statistic. For Uno’s C statistic we calcu-
lated confidence intervals from bootstrapping. A random
sub-sample of 15 % of the validation cohort was used as
the vast size of the dataset made computation of boot-
strap confidence intervals for the full sample unfeasible.
We assessed calibration by comparing the observed and
predicted dementia risk in the validation cohort per decile
of predicted risk, and computing the calibration slope. We
calculated the sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) using a
range of potential risk thresholds, to explore the clinical
utility of the risk algorithms.
Results
Development cohort study
We identified 930,395 eligible patients aged 60–95 years
in 377 practices in the development cohort study, of
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which 800,013 were aged 60–79 years and 130,382 aged
80–95 years at baseline (Fig. 1).
Development cohort aged 60–79 years
Baseline characteristics There were 413,974 (52 %)
women in the 60–79 years development cohort, the mean
age at baseline was 65.6 years (SD 6.1 years; Table 1).
Missing data on health measurements are detailed in
Additional file 1: Table A.1, with characteristics after
multiple imputation in Table A.2.
Incidence of dementia In the development cohort there
were 6,017 new diagnoses in 800,013 individuals with
3,205,190 Person Years at Risk (PYAR), corresponding
to a crude overall incidence of dementia of 1.88/1000
Table 1 Characteristics of development and validation cohorts for those aged 60–79 years (before multiple imputation)
Development cohort n = 800,013 Median
follow-up 5 years (IQR, 3.15–5 years)
Dementia events n = 6,017
Validation cohort n = 226,140 Median
follow-up 5 years (IQR, 3.27–5 years)
Dementia events n = 1,699
Obs Mean SD Obs Mean SD
Baseline age, years 800,013 65.6 6.08 226,140 65.6 6.11
Baseline total cholesterol, mmol/L 242,045 5.21 1.13 64,832 5.25 1.13
Baseline HDL cholesterol, mmol/L 167,937 1.42 0.41 45,682 1.42 0.42
Baseline weight, kg 226,671 79.2 16.9 59,594 79.1 16.8
Baseline systolic blood pressure, mmHg 452,306 142.4 17.0 125,744 142.7 17.1
Height, m 553,195 1.67 0.10 159,136 1.67 0.10
Baseline BMI, kg/m2 193,524 28.5 5.44 51,590 28.4 5.36
Baseline lipid ratio 166,420 3.88 1.17 45,352 3.91 1.17
Obs Freq % Obs Freq %
Sex 800,013 226,140
Men 386,039 48.3 109,108 48.3
Women 413,974 51.8 117,032 51.8
Local area deprivation score (quintiles) 800,013 226,140
1 (=least deprived) 218,198 27.3 71,040 31.4
2 194,637 24.3 57,763 25.5
3 166,956 20.9 42,278 18.7
4 134,103 16.8 33,945 15.0
5 (=most deprived) 86,119 10.8 21,114 9.3
Baseline smoking status 756,115 213,419
Never 323,345 42.8 96,256 45.1
Past 286,763 37.9 78,608 36.8
Current 146,007 19.3 38,555 18.1
History of very heavy drinking/alcohol problem 800,013 22,308 2.8 226,140 6,011 2.7
History of diabetes 800,013 70,377 8.8 226,140 18,662 8.3
History of coronary heart disease 800,013 93,408 11.7 226,140 26,016 11.5
History of stroke or transient ischemic attack 800,013 38,976 4.9 226,140 10,930 4.8
History of atrial fibrillation 800,013 24,763 3.1 226,140 7,085 3.1
Depression or use of anti-depressants at baseline 800,013 83,464 10.4 226,140 23,583 10.4
Anxiety or use of anxiolytics at baseline 800,013 29,690 3.7 226,140 8,549 3.8
Use of anti-hypertensive drugs at baseline 800,013 274,657 34.3 226,140 75,359 33.3
Use of statins at baseline 800,013 151,275 18.9 226,140 39,738 17.6
Use of hypnotics at baseline 800,013 30,787 3.9 226,140 8,736 3.9
Use of NSAIDs (other than aspirin) at baseline 800,013 98,397 12.3 226,140 27,546 12.2
Use of aspirin at baseline 800,013 127,550 15.9 226,140 34,756 15.4
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PYAR (95 % CI, 1.83–1.93) for 60–79 year olds. This in-
cluded 1,831 newly recorded diagnoses of Alzheimer’s
dementia, 1,308 of vascular dementia and 2,878 of un-
specified or mixed dementia during follow-up.
Associations of risk factors with new GP recorded
dementia diagnoses within 5 years Newly recorded
dementia diagnoses were associated with increasing age,
female sex, calendar year, and living in a deprived area
(Additional file 1: Table A.3). There were positive associ-
ations with current smoking, hazardous/harmful alcohol
drinking, and history of stroke/TIA, diabetes, CHD, atrial
fibrillation, or current depression/anti-depressant drug,
anxiety/anxiolytic drug, hypnotic drug, and aspirin use.
There were no significant associations with NSAIDs
(excluding aspirin) and anti-hypertensive drugs. There
was a small negative association with both BMI and
systolic blood pressure.
Selection of variables for risk model Following back-
wards elimination, age, sex, deprivation, calendar year, BMI,
current anti-hypertensive use, smoking status, hazardous/
harmful alcohol drinking, current depression, current as-
pirin use, and history of diabetes, stroke, TIA and atrial fib-
rillation were all retained in the model (Table 2). Because
statin use, lipid ratio, and SBP were all eliminated in the
backwards elimination, interaction terms for statin use*lipid
ratio and anti-hypertensive use*SBP were not considered.
Development cohort aged 80–95 years
Baseline characteristics There were 86,096 (66 %)
women in the 80–95 years development cohort, with a
mean age at baseline of 85 years (SD 3.9 years; Table 3).
Missing data on health measurements are reported in
Additional file 1: Table A.1. Characteristics after mul-
tiple imputation are reported in Table A.4.
Incidence of dementia In the 80–95 years development
cohort there were 1,483 newly recorded diagnoses of
Alzheimer’s dementia, 1,331 of vascular dementia, and
4,290 of unspecified or mixed dementia during follow-
up. In total, there were 7,104 new diagnoses in 429, 670
PYAR, corresponding to a crude incidence of dementia
Table 2 Final dementia risk model for cohort aged 60–79 years after backwards elimination (from development cohort)
Coefficienta 95 % CI HRa 95 % CI
Age, per year increase 0.209 0.200 to 0.219 1.23 1.22 to 1.25
Age2, per unit increase −0.003 −0.004 to −0.003 0.997 0.996 to 0.997
Gender (female vs. male) 0.129 0.074 to 0.183 1.14 1.08 to 1.20
Calendar year, per year increase 0.045 0.035 to 0.054 1.05 1.04 to 1.06
Local area deprivation score (quintile)
1 (=least deprived) 0 1
2 0.013 −0.063 to 0.090 1.01 0.94 to 1.09
3 0.118 0.041 to 0.194 1.13 1.04 to 1.22
4 0.202 0.123 to 0.280 1.22 1.13 to 1.32
5 (=most deprived) 0.226 0.138 to 0.314 1.25 1.15 to 1.37
BMI (kg/m2), per unit increase −0.062 −0.069 to −0.054 0.94 0.93 to 0.95
BMI2, per unit increase 0.003 0.002 to 0.003 1.003 1.002 to 1.003
Current anti-hypertensive use (yes vs. no) −0.132 −0.190 to −0.074 0.88 0.83 to 0.93
Smoking status
Never 0 1
Past −0.068 −0.127 to −0.009 0.93 0.88 to 0.99
Current −0.087 −0.168 to −0.005 0.92 0.85 to 1.00
History of alcohol problem (yes vs. no) 0.444 0.287 to 0.600 1.56 1.33 to 1.82
History of diabetes (yes vs. no) 0.287 0.205 to 0.368 1.33 1.23 to 1.45
Current depression/use of anti-depressants (yes vs. no) 0.834 0.770 to 0.897 2.30 2.16 to 2.45
History of stroke or transient ischemic attack (yes vs. no) 0.577 0.500 to 0.654 1.78 1.65 to 1.92
History of atrial fibrillation (yes vs. no) 0.221 0.120 to 0.322 1.25 1.13 to 1.38
Current aspirin use (yes vs. no) 0.253 0.189 to 0.316 1.29 1.21 to 1.37
aCoefficients and hazard ratios (HRs) are obtained by building Cox models separately within each of the 10 imputation datasets and then combining the results
using Rubin’s rules. Baseline 5-year survival function, So(5) = 0.9969
Age2 = age-squared i.e. the hazard ratio corresponds to the relative increase in hazard per unit increase in the quadratic function of age
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of 16.53/1000 PYAR (95 % CI, 16.15–16.92) for those
aged 80–95 years at baseline.
Associations of risk factors with new GP recorded
dementia diagnosis within 5 years New dementia diag-
noses were associated with increasing age and female
sex (Additional file 1: Table A.3). There were positive as-
sociations with history of stroke/TIA, diabetes, atrial
fibrillation, statin prescriptions, hazardous/harmful alco-
hol drinking, current depression/anti-depressant drugs,
anxiety/anxiolytic drugs, hypnotic drugs and aspirin use.
There were no significant associations with living in a
deprived area, CHD, and total cholesterol/HDL ratio.
There was a small negative association with current
smoking, BMI, systolic blood pressure, anti-hypertensive
drugs, and NSAIDs (excluding aspirin).
Table 3 Characteristics of development and validation cohorts for those aged 80–95 years (before imputation)
Development cohort n = 130,382 Median
follow-up 3.76 years (IQR, 1.71–5 years)
Dementia events n = 7,104
Validation cohort n = 38,084 Median
follow-up 3.92 years (IQR, 1.75–5 years)
Dementia events n = 1,923
Obs Mean SD Obs Mean SD
Baseline age, years 130,382 84.8 3.93 38,084 84.9 3.97
Baseline total cholesterol, mmol/L 26,841 4.99 1.19 6,785 5.08 1.21
Baseline HDL cholesterol, mmol/L 16,630 1.50 0.44 4,066 1.49 0.44
Baseline weight, kg 31,272 67.1 14.0 8,038 67.2 13.8
Baseline systolic blood pressure, mmHg 78,979 146.9 19.8 22,347 147.5 19.8
Height, m 62,622 1.62 0.10 17,616 1.62 0.10
Baseline BMI, kg/m2 24,091 25.7 4.65 6,213 25.7 4.53
Baseline lipid ratio 16,566 3.49 1.10 4,054 3.57 1.13
Obs Freq % Obs Freq %
Sex 130,382 38,084
Men 44,286 34.0 13,017 34.2
Women 86,096 66.0 25,067 65.8
Local area deprivation score (quintiles) 130,382 38,084
1 (=least deprived) 26,643 20.4 10,048 26.4
2 30,143 23.1 9,307 24.4
3 28,970 22.2 7,830 20.6
4 26,758 20.5 6,644 17.5
5 (=most deprived) 17,868 13.7 4,255 11.2
Baseline smoking status 113,391 32,702
Never 63,684 56.2 19,389 59.3
Past 39,778 35.1 10,697 32.7
Current 9,929 8.8 2,616 8.0
History of very heavy drinking/alcohol problem 130,382 921 0.7 38,084 250 0.7
History of diabetes 130,382 12,762 9.8 38,084 3,331 8.8
History of coronary heart disease 130,382 28,190 21.6 38,084 8,281 21.7
History of stroke or transient ischemic attack 130,382 20,221 15.5 38,084 5,824 15.3
History of atrial fibrillation 130,382 14,518 11.1 38,084 4,293 11.3
Depression or use of anti-depressants at baseline 130,382 17,201 13.2 38,084 4,886 12.8
Anxiety or use of anxiolytics at baseline 130,382 5,953 4.6 38,084 1,816 4.8
Use of anti-hypertensive drugs at baseline 130,382 58,323 44.7 38,084 16,396 43.1
Use of statins at baseline 130,382 16,546 12.7 38,084 4,111 10.8
Use of hypnotics at baseline 130,382 14,121 10.8 38,084 4,137 10.9
Use of NSAIDs (other than aspirin) at baseline 130,382 15,056 11.6 38,084 4,430 11.6
Use of aspirin at baseline 130,382 41,448 31.8 38,084 11,830 31.1
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Selection of variables for risk model Following back-
wards elimination, age, sex, calendar year, BMI, current
anti-hypertensive use, SBP, lipid ratio, smoking status,
hazardous/harmful alcohol drinking, current depression/
anti-depressants, current anxiety/anxiolytics, current as-
pirin use, current other NSAID use, and history of dia-
betes, stroke, or TIA and atrial fibrillation were all retained
in the model (Table 4). As statin use was excluded, the
interaction term statin use*lipid ratio was not considered.
An interaction term for SBP*anti-hypertensive use was
considered, but was not statistically significant (P = 0.6)
and therefore was not included.
Validation cohort study
We identified 264,224 eligible patients aged 60–95 years in
95 practices for the validation cohort, of which 226,140
were aged 60–79 years and 38,084 were aged 80–95 years
at baseline (Additional file 1: Figure A.1).
Validation cohort aged 60–79 years
Baseline characteristics/incidence of dementia The
characteristics of the validation cohort were similar to the
development cohort (Table 1). Missing data on health mea-
surements are reported in Additional file 1: Table A.1, with
characteristics after multiple imputation in Table A.2. In-
cidence rates for dementia were similar to those in the
development cohort, with 1,699 new diagnoses in
226,140 individuals with 915,380 PYAR, corresponding
to a crude overall incidence of dementia of 1.86/1000
PYAR (95 % CI, 1.77–1.95) for 60–79 year olds. This
included 528 newly recorded diagnoses of Alzheimer’s
dementia, 384 of vascular dementia, and 787 of unspeci-
fied or mixed dementia during follow-up.
Discrimination and calibration The model performed
well in terms of discrimination, with a Royston’s D stat-
istic of 2.03 (95 % CI, 1.95–2.11) and Uno’s C index 0.84
(95 % CI, 0.81–0.87). The calibration slope suggested
good calibration (0.98, 95 % CI, 0.93–1.02).
Risk classification Utilizing a range of possible cut-offs
to indicate ‘high risk’ for dementia, the specificity of the
risk algorithm was high but with lower sensitivity, and
there was a high NPV, but a low PPV (Table 5). For ex-
ample, if we chose a threshold to define high risk of 2 %,
the specificity would be 85.15 %, sensitivity 58.36 %, PPV
2.89, and NPV 99.63. We include details of how to calculate
the risk of dementia for a new patient in Additional file 1.
Table 4 Final dementia risk model for cohort aged 80–95 years after backwards elimination (development cohort)
Coefficienta 95 % CI HRa 95 % CI
Age, per year increase 0.055 0.047 to 0.062 1.06 1.05 to 1.06
Age2, per unit increase −0.005 −0.007 to −0.004 0.995 0.993 to 0.996
Gender (female v male) 0.160 0.104 to 0.216 1.17 1.11 to 1.24
Calendar year, per year increase 0.074 0.063 to 0.084 1.08 1.07 to 1.09
BMI (kg/m2), per unit increase −0.050 −0.063 to-0.036 0.95 0.94 to 0.96
Current anti-hypertensive use (yes vs. no) −0.249 −0.301 to −0.197 0.78 0.74 to 0.82
Systolic blood pressure (mmHg), per unit increase −0.006 −0.008 to −0.005 0.994 0.992 to 0.995
Lipid ratio (per unit increase) 0.042 −0.055 to 0.138 1.04 0.95 to 1.15
Smoking status
Never 0 1
Past −0.178 −0.233 to −0.122 0.84 0.79 to 0.89
Current −0.134 −0.229 to −0.039 0.88 0.80 to 0.96
History of alcohol problem (yes vs. no) 0.256 −0.009 to 0.521 1.29 0.99 to 1.68
History of diabetes (yes vs. no) 0.183 0.102 to 0.264 1.20 1.11 to 1.30
History of stroke or transient ischemic attack (yes vs. no) 0.242 0.177 to 0.306 1.27 1.19 to 1.36
History of atrial fibrillation (yes vs. no) 0.057 −0.018 to 0.132 1.06 0.98 to 1.14
Current depression/use of anti-depressants (yes vs. no) 0.400 0.335 to 0.465 1.49 1.40 to 1.59
Current anxiety/use of anxiolytics (yes vs. no) 0.136 0.034 to 0.237 1.15 1.04 to 1.27
Current NSAID use, excluding aspirin (yes vs. no) −0.157 −0.237 to −0.078 0.86 0.79 to 0.93
Current aspirin use (yes vs. no) 0.092 0.037 to 0.147 1.10 1.04 to 1.16
aCoefficients and hazard ratios (HRs) are obtained by building Cox models separately within each of the 10 imputation datasets and then combining the results
using Rubin’s rules. Baseline 5 year survival function, So(5) = −0.9277
Age2 = age-squared i.e. the hazard ratio corresponds to the relative increase in hazard per unit increase in the quadratic function of age
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Validation cohort aged 80–95 years
Baseline characteristics/incidence of dementia The
characteristics of those aged 80–95 years in the valid-
ation cohort were similar to the development cohort
(Table 3). Missing data on health measurements are re-
ported in Additional file 1: Table A.1, with characteristics
after multiple imputation in Table A.3. Incidence rates for
dementia were similar to those in the development co-
hort, with 1,923 new diagnoses in 38,084 individuals
with 127,510 PYAR, corresponding to a crude overall
incidence of dementia of 15.08/1000 PYAR (95 % CI,
14.42–15.77) for 80–95 year olds. This included 408
newly recorded diagnoses of Alzheimer’s dementia, 364
of vascular dementia, and 1,151 of unspecified or mixed
dementia during follow-up.
Discrimination and calibration The model from the
development cohort performed poorly in terms of dis-
crimination (Royston’s D statistic 0.86, 95 % CI, 0.76–0.95
and Uno’s C index 0.56, 95 % CI, 0.55–0.58) and calibra-
tion (calibration slope 1.04, 95 % CI, 0.89–1.18) when ap-
plied to the validation cohort. As this model performed
poorly we have not reported on risk classification.
Discussion
This study developed risk algorithms for predicting a
new recorded dementia diagnosis in two age groups in
primary care. In our validation study, the dementia risk
algorithm developed for the 60–79 year old population
performed well, but the algorithm for the older 80–95
years population did not. Our model is the first to be de-
rived entirely from routinely collected health data, which
can be calculated without collecting additional information
from the patient. In people aged between 60–79 years, the
dementia risk score included records of depression, stroke,
high alcohol consumption, diabetes, atrial fibrillation, as-
pirin use, smoking, decreasing weight, and untreated blood
pressure. Aspirin use may be a marker for underlying vas-
cular risk. The directions of associations of some factors,
such as weight and cholesterol, have been shown to change
in later life with the onset of disability, frailty and cognitive
decline and potential pre-clinical dementia [38, 39]. In our
study, the ‘high risk’ population may include those with
pre-clinical or undetected/recorded dementia, which may
explain some of the associations observed with individual
factors. Our algorithm uses routinely collected healthcare
data to predict the risk of a GP recorded diagnosis within
5 years, and the profile of risk factors within the score is
different to those aimed at identifying future risk, for
example mid-life risk scores for dementia [40].
At a low threshold of 1 %, our risk algorithm had a
sensitivity of 78 % and specificity of 73 %. With thresh-
olds of 2 % or above, our risk algorithm had higher spe-
cificity (85 %) but a correspondingly lower sensitivity
(58 %). In previous prediction models derived from co-
hort studies, models have generally had either high spe-
cificity with low sensitivity or vice versa [10, 11], and the
choice of threshold will depend on the intended use.
Strengths and limitations
Our development cohort study included more than
900,000 older people from across the UK registered
with THIN General Practices, with more than 13,000
new dementia events recorded. The findings are likely
to be generalizable to the UK population, but may not
be generalizable to other different healthcare settings.
The data source includes longitudinal data on a wide
range of potential risk factors, including demographic
factors, lifestyle, heath status measurements, medical
history/diagnoses, and drugs. We had power to con-
sider a wide range of potentially important risk factors,
in comparison to cohort studies with smaller samples
[10–20]. In those aged 60–79 years, we had good re-
cording of data for most factors, and for missing data
at baseline we used robust multiple imputation tech-
niques utilizing the entire patient record, taking into
account the longitudinal records rather than relying
solely on baseline parameters.
Using routinely collected data to develop the risk al-
gorithm has some inherent limitations. It may be less
complete in terms of potential predictor variables than co-
horts designed for research. The older cohort (80–95 years)
had fewer routine measurements of health status such as
Table 5 Risk classification using the 60–79 years dementia risk algorithm when applied to validation cohort
Cut off for high risk Sensitivity Specificity PPV NPV Patients classified
as high risk,
n (%)
Patients classified as
high risk who develop
dementia, n (%)
Patients classified
as low risk,
n (%)
Patients classified as
low risk who develop
dementia, n (%)
1 % 77.70 73.05 2.14 99.77 61,803 (27.33) 1,320 (2.14) 164,337 (72.67) 379 (0.23)
2 % 58.36 85.15 2.89 99.63 34,323 (15.18) 992 (2.89) 191,817 (84.82) 707 (0.37)
5 % 19.39 97.03 4.71 99.38 6,989 (3.09) 329 (4.71) 219,151 (96.91) 1,370 (0.62)
10 % 5.62 99.52 8.20 99.29 1,164 (0.51) 95 (8.2) 224,976 (99.49) 1,604 (0.71)
20 % 0.72 99.96 10.87 99.25 113 (0.05) 12 (10.87) 226,027 (99.95) 1,687 (0.75)
PPV, Positive predictive value; NPV, Negative predictive value
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BMI and lipid profile. The current validation applies to use
of the risk score in the case where the GP has complete in-
formation on the factors in the model. There were low
levels of missing data in some individuals on smoking sta-
tus and BMI for those 60–79 years, which we imputed for
our analysis. For all other factors in the final model, if
missing, the factor was presumed to be absent.
Some potential risk factors, such as family history of de-
mentia, physical activity or educational status, are poorly
recorded in routine UK primary care and could not be
included. Studies suggest that chronic and significant
medical diagnoses entered in electronic records are likely
to be accurate [25]. Other evidence suggests dementia is
under-recorded in primary care [41]. Our incidence rates
for dementia were lower than rates reported in studies
using screening, particularly for those over 80 years [42];
however, there is some evidence that dementia prevalence
is stabilizing more recently, despite population ageing
[43], and our study is based on more contemporary data.
This potential under-recording of dementia diagnoses in
GP records may lead to an underestimation of the true
predictive power of the risk score. In common with most
risk models, we only accounted for baseline variables and
for time-varying factors, exposure status may change
during the follow-up period. Routinely collected data
has the advantage of reflecting the data normally available
to a clinician in practice.
Implications
We used routinely collected primary care data to derive
a relatively simple new risk algorithm, predicting a new
GP recorded dementia diagnosis within 5 years, which
worked well in those aged 60–79 years, but not in older
age groups. This supports the previous suggestion that
given the steep rise in risk of dementia at 80 years, it
would be reasonable to test for dementia beyond this
point on the basis of age alone [19]. It is likely that risk
scores using traditional risk factors will not perform well
in this population, and a different approach might be
needed to identify a higher risk group aged 80 or above
using, for example, measures of frailty.
Our new dementia risk algorithm for 60–79 year olds
can be added to clinical software systems and a practice
could, for example, run this risk model on all eligible
people and offer those at risk more detailed testing or spe-
cific preventive management. Using a range of thresholds,
there was good specificity but lower sensitivity, and a very
high NPV but a low PPV. This risk algorithm may be
most helpful to ‘rule out’ those at low risk from dementia
case finding programs. This might avoid unnecessary in-
vestigations and anxiety for those at very low risk and
make these programs more cost-effective. The risk algo-
rithm may enable the identification of ‘at risk’ groups to
approach for future research studies. We report a range of
thresholds to allow clinicians or researchers to select the
threshold that gives the optimum balance of sensitivity
and specificity for dementia risk, depending on the
intended use.
Further research should be undertaken to explore the
performance of the Dementia Risk Score in different
settings and populations, including variations in per-
formance in areas where the prevalence, detection, and
recording of dementia by GPs is very low or very high.
We also need to further understand how the tool might
be used in practice, the ethical implications, and what
the impact of this might be for older people, clinicians,
and the potential costs for health services.
Conclusion
Routinely collected health data can predict five year risk
of recorded diagnosis of dementia in primary care for in-
dividuals aged 60-79 years, but not for those aged 80
years or more. This risk score can be used to identify
higher risk populations for dementia in primary care.
The risk score has a high negative predictive value and
may be most helpful in ‘ruling out’ those at very low risk
from further testing.
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